Navigation Links
InteKrin Therapeutics Announces Initiation of Phase 2b Study in Type 2 Diabetes with INT131
Date:2/25/2008

ortant milestone in bringing a novel, breakthrough therapeutic to patients which is complementary to other treatment modalities."

"There is a significant product profile gap in treating and improving insulin sensitivity in diabetic patients as a result of safety deficiencies with existing TZD therapy. INT131 is ideally positioned to potentially fulfill an unmet medical need for patients," said Denny Lanfear, InteKrin's President and CEO. "This study represents an important step in our overall global product development plan."

About InteKrin (http://www.InteKrin.com):

InteKrin Therapeutics is a privately-held clinical-stage drug development company focused on diabetes, obesity and metabolic disease. InteKrin's business strategy is to build a robust portfolio of high value products by in- licensing clinical-stage therapeutic candidates that address significant unmet medical needs and rapidly move them through critical development stages. InteKrin's team of world-class scientific and medical experts includes veterans from several successful BioPharma organizations, internationally recognized experts in nuclear receptors and metabolism, top scientists formerly with the Food and Drug Administration and key clinical and commercialization leaders.

To learn more about InteKrin, visit http://www.InteKrin.com.


'/>"/>
SOURCE InteKrin Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Oncology Drug Development Update - Molecular Profiling Redefines the Nature of Malignancy and Increases the Adoption of Targeted Therapeutics
2. TorreyPines Therapeutics Announces Strategic Plan with Focus on Clinical Development Activities to Maximize Value of Versatile Lead Compounds
3. Horizon Therapeutics Completes Enrollment in Phase 3 Trials for Lead Product Candidate HZT-501
4. Multiple Dose Clinical Trial of TorreyPines Therapeutics Tezampanel Demonstrates Compound is Safe and Well-Tolerated
5. PTC Therapeutics Announces Publication of Preclinical Data in PNAS
6. ImaRx Therapeutics Transitions Business Strategy
7. Protalix BioTherapeutics Extends Research Agreement With Yissum Based on Promising Acetylcholinesterase Program Results in Animal Study
8. Fundamental Applied Biology, Inc. Is Awarded SBIR Phase IIB Grant for the Commercialization of Protein Therapeutics Using Cell Free Technology
9. Juvaris BioTherapeutics Announces Cooperative Research and Development Agreement With The Centers for Disease Control and Prevention
10. Halozyme Therapeutics Announces Peer-Reviewed Publications of the INFUSE-LR Clinical Trial Results and Clinical Practice Experience With Hylenex
11. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/6/2009)...RNewswire-FirstCall/ -- Virtual Health Technologie... that the previously confirmed Letter of Intent to...gement Technologies, Inc (WNDM) is subject to fina...ders of VHGI. ,, Shareholder Assurances ,...royalty stream and cash realized from the transact...
(Date:11/6/2009)....C., Nov. 6 Chimerix, Inc., a biop...ntiviral therapeutics to address life-threatening ...the company,s lead antiviral compound, CMX001, to ... Health Security Initiative (GHSI). CMX001 is a b...the treatment of smallpox, as well as other seriou...
(Date:11/6/2009)...wire/ -- California American Water has designated ... Drain" week for its San Diego County service area...c and private agencies alike toward the common mis...ource water supplies. ,, California American Wa... drop off expired or unwanted pharmaceuticals free...
Breaking Medicine Technology:OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 2Chimerix Updates the World Health Organization and the Global Health Security Initiative on Development of CMX001 as a Broad-Spectrum Therapeutic for Smallpox 3California American Water Celebrates 'No Drugs Down the Drain' Week in San Diego 2New oral agents may prevent injury after radiation exposure 51333 1New oral agents may prevent injury after radiation exposure 51333 2University of Hawaii at Manoa professor published in science journal 9207 1A complete view of complexity in science and society in a new authoritative reference work 9205 1A complete view of complexity in science and society in a new authoritative reference work 9205 2
...007 - AVANIR,Pharmaceuticals (NASDAQ:AVNR) today a...d improvements in patient-centered outcomes in,pat...ain treated,with the investigational drug Zenvia(T...d in two scientific posters at the,Second Internat...Berlin, Germany on June 7 to 10, 2007., Both poste...
...Results of a Phase 2a,clinical trial evaluating th...t hospital acquired gram-negative bacterial,pneumo...iety (ATS),International Conference, May 18 - 23, ... Niederman, MD, Chairman, Department of, ... of, Medicine; Vice Chairman, Department...
Other Medicine Technology:AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 2AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 3AVANIR Pharmaceuticals to Present Zenvia Phase III Data in Diabetic,Peripheral Neuropathic Pain at Second International Congress on,Neuropathic Pain 4Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 2Clinical Trial Data (Phase 2a) Regarding Inhaled Amikacin Will Be,Presented at American Thoracic Society International Conference 3
(Date:11/7/2009)...USNewswire/ -- With the final House vote on health...ding the entire bill hostage to further their anti...go far beyond the status quo restrictions on abort...ill. In an outrageous amendment, which is expecte...ice Democrats are demanding explicit and unequivoc...
(Date:11/7/2009)...USNewswire/ -- Speaker Nancy Pelosi and Democratic...following a Democratic Whip meeting with President...peaker,s opening remarks: ,, "Thank you very m...s to receive the President of the United States on...vote and making progress for the American people. ...
(Date:11/7/2009)...h will rebel, expert says , , SATURDAY, No...behave badly if their parents expect them to, a ne...y are simply being realistic might actually contri...nan, a psychology professor at Wake Forest Univers...ty news release. "Negative expectations on the par...
(Date:11/7/2009)...nt economic climate, many Americans are monitoring...oney on what that they consider to be absolutely e...m believes that it’s very important for over...t to improve their health, and he is trying to mak...is tough economy by offering reasonable prices and...
(Date:11/6/2009)..., Nov. 6 /PRNewswire-FirstCall/ - Cardiome Pharma ...that it will report financial results for the thir...of Monday, November 9, 2009. Cardiome will hold a ...(6:00am Pacific) on that day to discuss the result...16-695-7806 or 888-789-9572 and reference conferen...
Breaking Medicine News(10 mins):Health News:Pelosi Remarks Following House Democrats' Meeting with President Obama 2Health News:Bad-Behaving Teens May Be Living Up to Expectations 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 2Health News:Dallas Bariatric Surgeon Offers Multiple Options for Patients Considering Weight Loss Surgery in a Rough Economy 3Health News:Cardiome to Release Third Quarter Results 2Health News:Cardiome to Release Third Quarter Results 3
... VALLEY, Calif., Feb. 12 Kovarus, Inc., a premier...xpert custom cycling shop in,Mill Valley, today jo...cated,to the promotion of cycling while also incre... , The Studio Velo/Kovarus Cycling Club (SVK-C...
...RIA, Calif., Feb. 12 The Centers for Disease Cont...eart disease is America,s leading cause of death. ...a new heart-related coronary attack, and about 470...de information about heart disease. The Internati...
...E, Md., Feb. 12 Neuralstem, Inc. (NYSE Alternext ... Senator (D-Tennessee) and former Ambassador to th...lstem Advisory Board and will serve as senior advi...om Tennessee in 1976 where he served for eighteen ...
....J., Feb. 12 DOR BioPharma, Inc. (OTC Bulletin Bo...at it has signed a potential $30 million partnerin... (Sigma - Tau) for the development and commerciali...upfront investment in DOR, inclusive of the $1.5 m...
... Where One Chicago Family Turned W... Chicago, IL (PRWEB) Febru... She is a grandmother of two. She is the primary ...ised her granddaughter, too. , , , , ,But what ha...
...la to Receive $75 Million Upfront Cash Payment, $5...yalties on Future Sales -- , , SOUTH SAN FRANCISC... a privately-held biopharmaceutical company develo...wide license agreement with Novartis to develop an...
Other Medicine News:Health News:Biking for Fun, Sport, and Brain Tumor Awareness 2Health News:Biking for Fun, Sport, and Brain Tumor Awareness 3Health News:The ISSA Offers 8 Tips for American Heart Month 2Health News:Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board 2Health News:Senator James Sasser, Former Ambassador to China, Joins Neuralstem Advisory Board 3Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 2Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 3Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 4Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 5Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 6Health News:DOR BioPharma Announces Potential $30 Million North American Partnership Agreement with Sigma-Tau Pharmaceuticals for orBec(R) in the Treatment of Graft-versus-Host Disease 7Health News:Taking Care of the Caregiver 2Health News:Taking Care of the Caregiver 3Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 2Health News:Portola Pharmaceuticals Enters Worldwide License Agreement for Development and Commercialization of Novel Antiplatelet Drug Elinogrel 3
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
...eference laboratory and a worldwide leader in inno...ffers an extensive test menu of highly complex and...hology. Owned by the University of Utah, ARUP Labo...tion's university teaching hospitals and children'...
Medicine Products: